Plus Therapeutics Inc SEC Filings

Plus Therapeutics (PSTV) reported an insider purchase by its Chief Financial Officer. On 11/04/2025, the CFO acquired 20,000 shares of common stock at a weighted average price of $0.51, with individual trades executed between $0.504 and $0.509. Following the transaction, the reporting person beneficially owns 68,138 shares, held directly.

The filing notes the purchase details were made across multiple trades, and the reporting person will provide a breakdown of shares bought at each price within the stated range upon request.

Plus Therapeutics (PSTV) filed its Q3 2025 10‑Q showing wider year‑to‑date losses but a stronger balance sheet from recent financings. The company reported a Q3 net loss of $4.4M on grant revenue of $1.4M. Operating expenses were driven by research and development of $2.4M and general and administrative of $3.4M.

Liquidity improved: cash and cash equivalents were $13.3M and total assets $18.7M at September 30, 2025. Stockholders’ equity turned positive to $5.1M from a deficit at year‑end, aided by capital raises, including sales under a Lincoln Park Purchase Agreement. Year‑to‑date financing cash inflows were $27.5M. The company recognized $3.8M in CPRIT grant revenue year‑to‑date; the $3.0M Department of Defense award remains deferred.

The filing states substantial doubt about continuing as a going concern due to ongoing losses and funding needs. Nasdaq confirmed compliance with equity standards, but PSTV remains out of compliance with the $1.00 minimum bid price requirement, with a grace period through November 12, 2025. Shares outstanding were 137,429,055 as of October 29, 2025.

Plus Therapeutics (PSTV) filed an 8-K stating it reported financial results for the third quarter ended September 30, 2025. The company furnished a press release with details as Exhibit 99.1, which is incorporated by reference.

The disclosure under Item 2.02 is furnished, not filed, under the Exchange Act. This routine update provides access to the company’s Q3 2025 results through the attached press release.

Plus Therapeutics (PSTV) disclosed a new long-term facility lease in Houston. The company agreed to lease approximately 11,370 rentable square feet at 6420 Levit Green Boulevard, with the lease expected to commence on or about November 1, 2026. The initial term is 120 calendar months.

Monthly base rent starts at $58,745 and increases annually by approximately 3%, plus the company’s share of the building’s direct expenses. This creates a multi-year operating commitment tied to growth and operational needs at the Houston site.

Marc H. Hedrick, who is both Chief Executive Officer and a Director of Plus Therapeutics, Inc. (PSTV), had restricted stock units vest on 10/01/2025. The vesting resulted in the acquisition of 159,681 shares of common stock at $0 cost per share because these were RSU settlements, and the filing reports Mr. Hedrick's direct beneficial ownership following the transaction as 180,106 shares in the non-derivative table and 1,756,487 shares in the derivative/underlying summary.

The Form 4 shows these RSUs vest in twelve substantially equal quarterly installments beginning on 10/01/2025, and that the report was submitted by an attorney-in-fact. This is a standard disclosure of insider equity vesting that increases the reporting person’s share holdings and signals management’s equity position without any cash purchase recorded.

Marc H. Hedrick, identified as Director and Chief Executive Officer of Plus Therapeutics, Inc. (PSTV), reported equity awards dated 08/13/2025 in an amended Form 4/A. The filing shows an award of 5,748,506 stock options with an exercise price of $0.5744 and an award of 1,916,168 Restricted Stock Units (RSUs). The RSUs vest over twelve quarters, beginning with the quarter ended September 30, 2025, and convert one-for-one into common shares on vesting. The amendment corrects previously disclosed vesting terms for the RSUs. The Form 4/A is signed by an attorney-in-fact on behalf of the reporting person on 10/03/2025.

Andrew John Hugh MacIntyre Sims, listed as Chief Financial Officer and Director of Plus Therapeutics, Inc. (PSTV), filed a Form 4 disclosing insider changes effective 10/01/2025. The filing reports the vesting of 38,323 Restricted Stock Units (RSUs) that are each a contingent right to one share, recorded with a transaction code M and a reported price of $0. After the reported transaction the filing shows 48,138 shares of Common Stock beneficially owned directly and 421,555 derivative securities (RSUs) reported as beneficially owned following the transaction. The filing states these RSUs vest in twelve substantially equal quarterly installments beginning on 10/01/2025.

PLUS THERAPEUTICS, INC. (PSTV) disclosure shows an amendment to an insider Form 4 for Andrew Sims, the company's Chief Financial Officer, correcting previously reported vesting terms. On 08/13/2025 Mr. Sims was awarded 1,379,636 stock options with an exercise price of $0.5744 and 459,878 restricted stock units (RSUs). The options vest over four years in equal monthly 1/48th installments and expire 08/12/2035. The amended RSU disclosure clarifies they vest over twelve quarters in substantially equal 1/12th increments beginning with the quarter ended 09/30/2025 and convert one-for-one into common shares upon vesting. The filing is signed by Mr. Sims on 10/03/2025.